checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr
Company profile
Ticker
CKPT
Exchange
Website
CEO
James F. Oliviero
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CKPT stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
8 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
S-3
Shelf registration
29 Mar 24
PRE 14A
Preliminary proxy
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
22 Mar 24
8-K
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
18 Mar 24
D
Exempt offering of security
5 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Feb 24
Latest ownership filings
SC 13D/A
Fortress Biotech, Inc.
22 Mar 24
4
Change in insider ownership
22 Mar 24
3
Sharma Amit
19 Mar 24
4
James F Oliviero III
1 Mar 24
4
WILLIAM GARRETT GRAY
1 Mar 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
WILLIAM GARRETT GRAY
2 Feb 24
4
James F Oliviero III
2 Feb 24
5
James F Oliviero III
2 Feb 24
4
Change in insider ownership
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.77 mm | 1.77 mm | 1.77 mm | 1.77 mm | 1.77 mm | 1.77 mm |
Cash burn (monthly) | 1.88 mm | 1.56 mm | 2.57 mm | 4.89 mm | 4.92 mm | 4.67 mm |
Cash used (since last report) | 12.92 mm | 10.69 mm | 17.61 mm | 33.52 mm | 33.73 mm | 32.05 mm |
Cash remaining | -11.15 mm | -8.92 mm | -15.84 mm | -31.74 mm | -31.96 mm | -30.28 mm |
Runway (months of cash) | -5.9 | -5.7 | -6.2 | -6.5 | -6.5 | -6.5 |
Institutional ownership, Q3 2023
20.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 9 |
Closed positions | 5 |
Increased positions | 18 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 6.56 bn |
Total shares | 7.00 mm |
Total puts | 25.20 k |
Total calls | 19.80 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
FBIO Fortress Biotech | 2.44 mm | $3.54 mm |
Armistice Capital | 2.06 mm | $3.51 bn |
CVI Investments | 636.96 k | $1.69 mm |
Vanguard | 482.64 k | $820.48 mm |
Sabby Management | 205.25 k | $348.92 mm |
Geode Capital Management | 172.95 k | $294.10 mm |
PVG Asset Management | 111.03 k | $188.74 mm |
Advisor | 107.09 k | $182.04 mm |
BLK Blackrock | 103.69 k | $176.27 mm |
Legacy Wealth Asset Management | 85.00 k | $144.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Mar 24 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 193,905 | 0.00 | 2,096,278 |
28 Feb 24 | Gray William Garrett | Common Stock | Sell | Dispose S | No | No | 2.07 | 2,035 | 4.21 k | 145,224 |
28 Feb 24 | James F Oliviero III | COMMON STOCK | Gift | Dispose G | No | No | 0 | 9,056 | 0.00 | 341,780 |
28 Feb 24 | James F Oliviero III | COMMON STOCK | Sell | Dispose S | No | No | 2.06 | 5,894 | 12.14 k | 350,836 |
1 Feb 24 | Gray William Garrett | Common Stock | Sell | Dispose S | No | No | 1.95 | 4,115 | 8.02 k | 147,259 |
News
HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
22 Mar 24
Checkpoint Therapeutics FY23 EPS $(3.17) Vs $(7.09) YoY; As Of December 31, 2023, Checkpoint's Cash And Cash Equivalents Totaled $4.9M
22 Mar 24
Pinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are Selling
5 Feb 24
Press releases
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Checkpoint, Sonder, and Perion and Encourages Investors to Contact the Firm
24 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT
24 Apr 24
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
24 Apr 24
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
23 Apr 24
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
23 Apr 24